A phase II trial reported that adding toripalimab, an anti‑PD‑1 antibody, to standard FLOT chemotherapy produced encouraging responses in patients with metastatic gastric cancer involving peritoneal metastases. Investigators observed improved chemo-sensitivity and tolerability in a difficult-to-treat subgroup, suggesting immune-checkpoint addition may extend benefits of established cytotoxic regimens. The data support moving the combination into larger, controlled studies to assess survival endpoints and potential biomarkers of response.